Island Pharmaceuticals (ASX:ILA) Cash, Cash Equivalents, Marketable Securities : A$0.98 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals Cash, Cash Equivalents, Marketable Securities?

Island Pharmaceuticals's quarterly cash, cash equivalents, marketable securities declined from Dec. 2022 (A$3.43 Mil) to Jun. 2023 (A$2.00 Mil) but then stayed the same from Jun. 2023 (A$2.00 Mil) to Dec. 2023 (A$0.98 Mil).

Island Pharmaceuticals's annual cash, cash equivalents, marketable securities declined from Jun. 2021 (A$6.46 Mil) to Jun. 2022 (A$4.79 Mil) and declined from Jun. 2022 (A$4.79 Mil) to Jun. 2023 (A$2.00 Mil).

Island Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Island Pharmaceuticals's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Island Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Chart

Island Pharmaceuticals Annual Data

Trend

Jun21

Jun22

Jun23

Cash, Cash Equivalents, Marketable Securities

6.46

4.79

2.00

Island Pharmaceuticals Semi-Annual Data
	Jun20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			5.83	4.79	3.43	2.00	0.98

Island Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Island Pharmaceuticals (ASX:ILA) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Island Pharmaceuticals Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Island Pharmaceuticals's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Island Pharmaceuticals (ASX:ILA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124

Website

https://www.islandpharmaceuticals.com

Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its lead asset ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases.

Island Pharmaceuticals (ASX:ILA) Headlines

No Headlines